When is a TNFi preferred over a JAKi?

TNFi preferred: age ≥65 or high cardiovascular/VTE risk (JAK ORAL Surveillance data), personal or family history of malignancy, active infection risk, pregnancy planning. JAKi preferred: convenience (oral), inadequate TNFi response, seronegative RA, or certain comorbidities.

What are the major JAK inhibitor safety concerns?

Based on ORAL Surveillance: major adverse cardiovascular events (MACE), VTE, malignancy, and serious infections were more frequent with tofacitinib vs adalimumab in RA patients ≥50 with CV risk factors.

Which JAK inhibitors are approved for RA?

FDA-approved JAKi for RA: tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq), filgotinib (Jyseleca, EU only). All carry boxed warning for serious infections, malignancy, and cardiovascular risk.

JAK Inhibitor vs TNF Inhibitor bDMARD Selection Calculator

Guide biologic DMARD selection in rheumatoid arthritis and other inflammatory arthritides. Weighs disease features, comorbidities (cardiovascular risk, VTE risk, malignancy), and drug contraindications against JAKi and TNFi profiles.

Use the full interactive calculator below, or

Related Calculators

DAS28-CRP RA

Hyper-niche Medical

JAK Inhibitor vs TNF Inhibitor bDMARD Selection Calculator

Related Calculators

Frequently Asked Questions

When is a TNFi preferred over a JAKi?

What are the major JAK inhibitor safety concerns?

Which JAK inhibitors are approved for RA?